Popular Articles
Stretch Mark

Rigel's R788 Evaluated In Phase 2 Trial In Multiple Cancers
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. This open-label, single arm clinical trial will include patients with advanced colorectal, thyroid, non-small cell lung, hepatocellular, head and neck, or renal cell cancers who have failed to respond to at least one line of therapy.
generic viagra online
Vimpat(R) (lacosamide) C-V, A New Antiepileptic Drug (AED), To Be Available In U.S. Pharmacies
Vimpat(R) (lacosamide) C-V, a new antiepileptic drug (AED), will be available in U.S. pharmacies by the first week of June 2009. Vimpat was approved by the U.S. FDA in the fall of 2008 for the use as an add-on therapy for the treatment of partial-onset seizures in people 17 years and older with epilepsy.
News of the day
Mexican, Chilean Presidents Appeal For Developing Countries Access To H1N1 Vaccine
Mexican President Felipe Calderon and Chilean President Michelle Bachelet on Thursday emphasized the importance of developing countries having access to a vaccine that offers protection against the H1N1 (swine flu), "that has killed over 200 people and infected tens of thousands worldwide," AFP/MSN Philippine News reports.
Sexual Health

Study Links Recurrence Of Abnormal Cervical Cells To Age, Treatment Type

Older women, women with a higher grade of precancerous cells and women who undergo a freezing procedure known as cryotherapy to remove abnormal cervical cells are at a higher risk than other groups that the problem cells will return or develop into cervical cancer, according to a study published in the Journal of the National Cancer Institute, Reuters reports. For the study, Joy Melnikow of the University of California-Davis and colleagues compared 37,000 women who were treated for cervical intraepithelial neoplasia -- abnormal cervical cells -- from 1986 through 2000 with 71,000 women who had no history of abnormal cervical cells.The researchers found that the risk of cervical cancer and recurrence of medium to severe degrees of CIN was highest for women who were older than age 40, who had been previously treated for severe CIN or whose abnormal cells were treated using cryotherapy. The women underwent cone biopsies a surgical procedure to remove abnormal cells were least likely to have a recurrence of CIN. According to Melnikow, recurrence was most likely to occur within the first six years after treatment. Melnikow said that women who have been treated surgically have higher risks of bleeding and preterm labor. Therefore, younger women who are planning to become pregnant might prefer cryotherapy, she said, adding that younger women"s "risk of recurrence is lower, and a recurrence can be treated again" (Steenhuysen, Reuters, 5/12). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):